Last reviewed · How we verify
NCT05226546
Effectiveness and Safety of Platelet Rich Plasma (PRP) on Persistent Olfactory Dysfunction Related to COVID-19
Phase 2, PHASE3 trial testing Platelet rich plasma (PRP) in Anosmia in 56 participants. Completed in 1 August 2021.
1 August 2021
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire Saint Pierre |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 56 |
| Start date | 1 February 2021 |
| Primary completion | 1 August 2021 |
| Estimated completion | 1 August 2021 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- Platelet rich plasma (PRP) — full drug profile →
- olfactory training
Conditions studied
Sponsor
Centre Hospitalier Universitaire Saint Pierre
Who can join
18 and older, any sex, with Anosmia or COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Olfactory dysfunction (OD) is a well know symptom of coronavirus disease 2019 (COVID-19), accounting for 48 to 85% of patients. In 1 to 10% of cases, patients develop a chronic olfactory dysfunction (COD,) lasting more than 6 months. Recently, platelet-rich plasma (PRP) was used in patients with non-COVID-19 COD and authors reported encouraging results. In the present study, the investigators investigated the usefulness and safety of PRP injection in 56 patients with COVID-19 COD. Our results showed that PRP in the olfactory cleft can increase the olfactory threshold one month after the injection. Moreover, our results suggest that timing of treatment may be an important factor and that PRP is a safe treatment because no adverse effects were reported throughout the study
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Effectiveness and safety of PRP on persistent olfactory dysfunction related to COVID-19.
Steffens Y, Le Bon SD, Lechien J, Prunier L, et al · · 2022 · cited 28× · PMID 35904632 · DOI 10.1007/s00405-022-07560-y -
Post-COVID-19 Anosmia and Therapies: Stay Tuned for New Drugs to Sniff Out.
Riccardi G, Niccolini GF, Bellizzi MG, Fiore M, et al · · 2023 · cited 11× · PMID 37366867 · DOI 10.3390/diseases11020079
Verify or expand the search:
- PubMed search for NCT05226546
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Platelet rich plasma (PRP)
Trials testing the same drug.
- NCT06193499 — A Study on the Effect of High-concentrated Platelet Rich Plasma (PRP) on Osteoarthritis in the Thumb Base. · NA · recruiting
- NCT06849674 — Efficacy and Safety of Platelet-Rich Plasma as an Intraoperative Holding Solution in Hair Transplantation · NA · completed
- NCT06685393 — Efficacy of Injectable Platelet-rich Fibrin Versus Platelet-Rich Plasma As Adjunctive to Scaling and Root Planning in No · NA · completed
- NCT04492748 — Rotator Cuff Tendinopathy Conservative Treatment With Collagen, PRP or Both · Phase 4 · unknown
- NCT03379883 — Genicular Nerve and Intra-articular Radiofrequency Versus Platelet Rich Plasma Injection for Knee Osteoarthritis · NA · unknown
Other recruiting trials for Anosmia
Currently open trials in the same condition.
- NCT06733636 — Scents of Progress: Leveraging a Novel Device for Olfactory Training in Older Adults · NA · recruiting
- NCT05562050 — Characteristics of the Anosmic Olfactory Mucosa · active not recruiting
- NCT05040659 — Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2 · active not recruiting
- NCT05364125 — Olfactory Training on Smell Dysfunction Patients in HK · NA · recruiting
- NCT06423495 — Efficacy of Photobiomodulation in the Rehabilitation of Olfactory Dysfunctions Induced by Long COVID-19 · NA · recruiting
Other Centre Hospitalier Universitaire Saint Pierre trials
Trials by the same sponsor.
- NCT06814600 — Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients · recruiting
- NCT06214312 — Pulmonary Ultrasound for the Assessment of Atelectasis in Anesthetized Children Using a Laryngeal Mask Airway. · completed
- NCT05856396 — Maternal Determinants of Infant Immunity to Pertussis · Phase 4 · completed
- NCT05898737 — Nociception Level Index (NOL Index) for Obstetrical Pain Assessment Under Epidural Analgesia. · unknown
- NCT05848531 — Clonidine With Morphine in Patient Controlled Analgesia Pump in Vaso-Occlusive Crisis in Sickle Cell Disease Patient · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05226546 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire Saint Pierre
- Last refreshed: 25 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05226546.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing